NZ607630A - Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) - Google Patents

Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)

Info

Publication number
NZ607630A
NZ607630A NZ607630A NZ60763011A NZ607630A NZ 607630 A NZ607630 A NZ 607630A NZ 607630 A NZ607630 A NZ 607630A NZ 60763011 A NZ60763011 A NZ 60763011A NZ 607630 A NZ607630 A NZ 607630A
Authority
NZ
New Zealand
Prior art keywords
matrix
protective film
active
gestodene
ingredient
Prior art date
Application number
NZ607630A
Other languages
English (en)
Inventor
Stefan Bracht
Ildiko Terebesi
Thomas Langguth
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ607630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of NZ607630A publication Critical patent/NZ607630A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ607630A 2010-09-06 2011-09-02 Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) NZ607630A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010040299A DE102010040299A1 (de) 2010-09-06 2010-09-06 Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
PCT/EP2011/065204 WO2012031985A1 (de) 2010-09-06 2011-09-02 Transdermale therapeutische systeme mit kristallisationsinhibierender schutzfolie (release liner)

Publications (1)

Publication Number Publication Date
NZ607630A true NZ607630A (en) 2015-02-27

Family

ID=44653285

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ607630A NZ607630A (en) 2010-09-06 2011-09-02 Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)

Country Status (33)

Country Link
US (2) US8557279B2 (enExample)
EP (1) EP2613771A1 (enExample)
JP (2) JP6104800B2 (enExample)
KR (1) KR20130114127A (enExample)
CN (1) CN103079549B (enExample)
AP (1) AP3586A (enExample)
AR (1) AR082907A1 (enExample)
AU (1) AU2011298892B2 (enExample)
BR (1) BR112013005305A2 (enExample)
CA (1) CA2810103C (enExample)
CL (1) CL2013000636A1 (enExample)
CO (1) CO6690753A2 (enExample)
CR (1) CR20130098A (enExample)
CU (1) CU24172B1 (enExample)
DE (1) DE102010040299A1 (enExample)
DO (1) DOP2013000053A (enExample)
EA (1) EA032575B1 (enExample)
EC (1) ECSP13012477A (enExample)
GT (1) GT201300062A (enExample)
IL (2) IL224980A (enExample)
MA (1) MA34581B1 (enExample)
MX (1) MX2013002602A (enExample)
MY (1) MY162768A (enExample)
NZ (1) NZ607630A (enExample)
PE (2) PE20131138A1 (enExample)
PH (1) PH12013500429A1 (enExample)
SG (2) SG10201506927TA (enExample)
TN (1) TN2013000087A1 (enExample)
TW (1) TWI576245B (enExample)
UA (1) UA110217C2 (enExample)
UY (1) UY33590A (enExample)
WO (1) WO2012031985A1 (enExample)
ZA (1) ZA201301389B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (enExample) * 1987-04-02 1990-06-29 Ciba Geigy Ag
DE58909570D1 (de) 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
MX9101787A (es) 1990-10-29 1992-06-05 Alza Corp Formulaciones,metodos y dispositivos anticonceptivos transdermicos
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
NZ518723A (en) 1999-11-24 2004-04-30 Agile Therapeutics Inc Improved transdermal contraceptive delivery system and process
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
AU2002235155A1 (en) 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
EP1216699A1 (de) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Transdermalsystem enthaltend ein hochpotentes Gestagen
US20030165547A1 (en) * 2001-05-18 2003-09-04 Elisabeth Picard-Lesboueyries Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
ME00147B (me) * 2003-02-21 2010-10-10 Schering Ag Uv-stabilni transdermalni flasteri
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
JP4965263B2 (ja) 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
MX2007004315A (es) * 2004-10-08 2008-03-11 Noven Pharma Dispositivo para suministro transdermico de farmaco que incluye un respaldo oclusivo.
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
AU2009302853B2 (en) * 2008-10-06 2014-09-11 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Also Published As

Publication number Publication date
IL224980A (en) 2017-07-31
PE20180198A1 (es) 2018-01-26
JP2016216500A (ja) 2016-12-22
AU2011298892B2 (en) 2015-03-12
US20140018751A1 (en) 2014-01-16
MY162768A (en) 2017-07-14
JP6104800B2 (ja) 2017-03-29
US20120082714A1 (en) 2012-04-05
TN2013000087A1 (en) 2014-06-25
PE20131138A1 (es) 2013-10-26
AP2013006787A0 (en) 2013-04-30
ZA201301389B (en) 2021-05-26
SG187941A1 (en) 2013-04-30
MX2013002602A (es) 2013-04-08
TW201217165A (en) 2012-05-01
EP2613771A1 (de) 2013-07-17
IL251124B (en) 2020-07-30
UA110217C2 (en) 2015-12-10
CU20130031A7 (es) 2013-05-31
IL251124A0 (en) 2017-04-30
EA032575B1 (ru) 2019-06-28
GT201300062A (es) 2015-01-16
JP2013536828A (ja) 2013-09-26
TWI576245B (zh) 2017-04-01
CO6690753A2 (es) 2013-06-17
WO2012031985A1 (de) 2012-03-15
AU2011298892A1 (en) 2013-03-28
US8557279B2 (en) 2013-10-15
AR082907A1 (es) 2013-01-16
US9060955B2 (en) 2015-06-23
CN103079549B (zh) 2016-11-02
ECSP13012477A (es) 2013-04-30
CR20130098A (es) 2013-05-15
AP3586A (en) 2016-02-10
BR112013005305A2 (pt) 2016-08-16
DOP2013000053A (es) 2013-07-15
CN103079549A (zh) 2013-05-01
CA2810103A1 (en) 2012-03-15
EA201390246A1 (ru) 2013-09-30
PH12013500429A1 (en) 2019-10-07
KR20130114127A (ko) 2013-10-16
CL2013000636A1 (es) 2013-09-13
CU24172B1 (es) 2016-04-25
UY33590A (es) 2011-10-31
MA34581B1 (fr) 2013-10-02
CA2810103C (en) 2019-06-18
DE102010040299A1 (de) 2012-03-08
SG10201506927TA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
EP2848248A3 (en) Amorphous drug transdermal systems, manufacturing methods, and stabilization
JP2013079281A5 (enExample)
MX337361B (es) Sistema de entrega de medicamento transdermico que comprende una capa de liberacion recubierta.
RU2014111255A (ru) Трансдермальная терапевтическая система для гидрохлорида 5-аминолевулиновой кислоты
NZ611920A (en) Percutaneous absorption preparation containing rivastigmine
BR9912210A (pt) Sistema terapêutico transdermal, contendo hormÈnios e inibidores de cristalização
HK1216503A1 (zh) 用於經皮傳遞安非他命的組合物及方法
NZ607630A (en) Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
JP2002518430A5 (enExample)
EP2457565A1 (de) Transdermales therapeutisches System enthaltend Rotigotin
JP2013536828A5 (enExample)
JP5410071B2 (ja) エステル化抑制剤及びエステル化抑制方法
KR20060100411A (ko) 부착제
JP5181320B2 (ja) 皮膚刺激の少ない経皮吸収型製剤
US20220110885A1 (en) Transdermal therapeutics system with barrier layer
JP6100150B2 (ja) 4−アミノピリジン含有貼付剤
TW200719902A (en) Solid transdermal therapeutic system with uv absorber
JP4733416B2 (ja) 貼付剤
JP2005170938A (ja) 貼付剤
JP2006151886A (ja) 角質剥離が少ない貼付剤

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 SEP 2016 BY HENRY HUGHES IP LIMITED

Effective date: 20150622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 SEP 2017 BY CPA GLOBAL

Effective date: 20160819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 SEP 2018 BY CPA GLOBAL

Effective date: 20170817

LAPS Patent lapsed
ASS Change of ownership

Owner name: LUYE PHARMA SWITZERLAND AG, CH

Effective date: 20190814

S35A Application for proceedings under section 35 (restoration of lapsed patents)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 SEP 2021 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20200824

LAPS Patent lapsed